Citations

Showing 10 of 108152 citations.

Rates of Diplopia in Ahmed FP7, Baerveldt 250, and 350 Glaucoma Patients Compared With Medical Controls
Kilgore, Khin P. , Stern, Nicole Caroline, Sabbagh, Nouran, Jamali, Sepideh, White, Launia J. , Sit, Arthur J. , Bitrian, Elena , Roddy, Gavin W. , Khanna, Cheryl L. , Sit, Arthur J , Wang, Feng

Mayo Clinic

Journal of Glaucoma | May 28, 2021 | Volume: 30 | Issue: 7 | Pages: 579-584

10.1097/ijg.0000000000001886 | PMID 34049345 Get It

Precis: Diplopia was present in ~20% of patients with Ahmed FP7 (FP7) or Baerveldt 350 (B350), compared with 5% to 6% in those with Baerveldt 250 (B250) or controls, suggesting risk of diplopia should be included in preoperative counseling. Purpose: The purpose of this study was to examine the prevalence of diplopia and strabismus in patients with B250, B350, or FP7 glaucoma drainage devices (GDD). Materials and Methods: In this cohort study, glaucoma patients 18 years and above who had received, or would be receiving, a B250, B350, or FP7 GDD, and medically treated controls were consecutively enrolled from August 8, 2017, through July 31, 2019. The Diplopia Questionnaire was administered ≥30 days postoperatively, and upon enrollment to the controls. All diplopic patients underwent orthoptic measurements, which were reviewed by a strabismus specialist. Patients with GDDs in quadrants other than superotemporal, multiple GDDs, or scleral buckles were excluded. Bonferroni correction was applied for pairwise comparisons. Results: Diplopia was reported in 23/129 (17.8%) GDD patients and 5/99 (5.1%) control patients (P=0.003): 8/35 (22.9%) FP7, 2/32 (6.3%) B250, and 13/62 (21.0%) B350, with significant differences between FP7 versus controls (P=0.014) and B350 versus controls (P=0.011). Diplopia was attributable to GDD in 2 FP7 (5.9%, 95% confidence interval: 0.7-19.2), 0 B250, and 4 B350 (6.5%, 95% confidence interval: 1.7-15.2) patients, without significant differences between the GDDs. Conclusions: Patients with the larger (B350) or the higher profile plate (FP7) GDDs were more likely to experience diplopia than controls, and diplopia was attributable to the GDD in ~6% of patients with either a FP7 or a B350 GDD. Since diplopia can affect patients’ quality of life, preoperative counseling for GDD surgery, particularly B350 and FP7, should include a discussion of the risk of diplopia.
Good Surgical Outcomes After Concomitant Repair of Double Radial Tears of the Lateral Meniscus and Anterior Cruciate Ligament Reconstruction
Leafblad, Nels D. , Keyt, Lucas K. , Cook, Corey S., Smith, Patrick A. , Krych, Aaron J. , Krych, Aaron J , Stuart, Michael J.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | May 28, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1016/j.asmr.2021.02.005 | PMID 34430877 Get It

Purpose To describe double radial tears of the lateral meniscus (LM), report early clinical treatment outcomes, and determine reoperation and failure rates. Methods Twenty‐one (N = 21) consecutive cases of arthroscopic‐treated lateral meniscus double radial tears treated between 2012 and 2018 were reviewed, including 15 males (71.4%) and 6 females (28.6%). Meniscus repairs were all performed at the time of anterior cruciate ligament (ACL) reconstruction. Patients with associated fractures or prior surgeries were excluded. Concomitant injuries were reported, as were preinjury and postoperative Tegner scores, preoperative and postoperative visual analogue pain scale (VAS) scores, and postoperative International Knee Documentation Committee (IKDC) subjective scores. Reoperation and failure rates were documented. Results Twenty‐one (N = 21) tears were located in the posterior horn of the meniscus near the root attachment; 15 (71.4%) underwent all‐inside repair, 4 (19.0%) underwent transtibial pull‐through repair, 1 (4.8%) was partially debrided, and 1 (4.8%) was left untreated. Twenty‐one tears (N = 21) were in the body of the meniscus; 7 (33.3%) were repaired, 7 (33.3%) were partially debrided, and 7 (33.3%) were left untreated. Thirteen patients (62%) had associated medial collateral ligament (MCL) injuries. Mean follow‐up was 2.6 years. VAS at rest and with activity improved by 2.1 points ( P < .001) and 3.1 points ( P = .017) after surgery. The mean postoperative Tegner activity score was 6.4, and the mean IKDC score was 83.2 at final follow‐up. Reoperation was required in 5 patients (23.8%), and the surgical treatment failed in 1 patient (4.7%). Conclusions Double radial tears of the LM are uncommon injuries that occur in the setting of ACL tears, usually combined with MCL injury. The variety of surgical treatment techniques have a low failure rate at short‐term follow‐up. Patients tend to have good clinical outcomes with improvement in pain and overall function after surgically treating these injuries with simultaneous ACL reconstruction. Level of Evidence Level IV, therapeutic study, case series
Donor Warm Ischemia Time in DCD Liver Transplantation—Working Group Report From the ILTS DCD, Liver Preservation, and Machine Perfusion Consensus Conference
Kalisvaart, Marit , Croome, Kristopher P. , Cerisuelo, Miriam Cortés , Abt, Peter L. , Croome, Kris P , Pirenne, Jacques , Miñambres, Eduardo

Mayo Clinic

Transplantation | May 28, 2021 | Volume: 105 | Issue: 6 | Pages: 1156-1164

10.1097/tp.0000000000003819 | PMID 34048418 Get It

Donation after circulatory death (DCD) grafts are commonly used in liver transplantation. Attributable to the additional ischemic event during the donor warm ischemia time (DWIT), DCD grafts carry an increased risk for severe ischemia/reperfusion injury and postoperative complications, such as ischemic cholangiopathy. The actual ischemia during DWIT depends on the course of vital parameters after withdrawal of life support and varies widely between donors. The ischemic period (functional DWIT) starts when either Sp o 2 or blood pressure drop below a certain point and lasts until the start of cold perfusion during organ retrieval. Over the years, multiple definitions and thresholds of functional DWIT duration have been used. The International Liver Transplantation Society organized a Consensus Conference on DCD, Liver Preservation, and Machine Perfusion on January 31, 2020 in Venice, Italy. The aim of this conference was to reach consensus about various aspects of DCD liver transplantation in context of currently available evidence. Here we present the recommendations with regards to the definitions used for DWIT and functional DWIT, the importance of vital parameters after withdrawal of life support, and acceptable thresholds of duration of functional DWIT to proceed with liver transplantation.
Ondine’s Curse and Trismus in Association With Kelch-like Protein-11 Autoimmunity
Devine, Michelle F., Gay, Peter C. , Dubey, Divyanshu

Mayo Clinic

JAMA Neurology | May 28, 2021 | Volume: 78 | Issue: 8 | Pages: 1016

10.1001/jamaneurol.2021.1557 | PMID 34047764 Get It

Inhibition of T-Cell Antigen Receptor-Mediated Transmembrane Signaling by Protein Kinase C Activation
Abraham, Robert T. , Ho, Steffan N., Barna, Thomas J., Rusovick, Karna M., McKean, D J

Mayo Clinic

Molecular and Cellular Biology | May 28, 2021 | Volume: 8 | Issue: 12 | Pages: 5448-5458

10.1128/mcb.8.12.5448-5458.1988 | PMID 2977423 Get It

What’s New in Musculoskeletal Infection
Fehring, Thomas K. , Fehring, Keith A. , Hewlett, Angela , Higuera, Carlos A. , Otero, Jesse E. , Tande, Aaron J. , Tande, Aaron , Higuera, Carlos

Mayo Clinic

Journal of Bone and Joint Surgery | May 28, 2021 | Volume: 103 | Issue: 14 | Pages: 1251-1258

10.2106/jbjs.21.00311 | PMID 34048412 Get It

SARS-CoV-2 Related Ischemic Colitis in an Adolescent With Trisomy 21: Diagnostic Pitfalls and Considerations
Ma, Yiming , Deutsch, Gail , Tassel, Dane Van , Shub, Mitchell , Schroeder, Shauna , Krauss, Jennifer L., Davenport, Katherine P., Carpentieri, David , Carpentieri, David , Ma, Y

Mayo Clinic

Pediatric and Developmental Pathology | May 28, 2021 | Volume: 24 | Issue: 5 | Pages: 445-449

10.1177/10935266211015666 | PMID 34048305 Get It

Millions of patients seek medical attention for diarrhea, vomiting, nausea, and abdominal pain. In the current environment, it is important to recognize that these symptoms may be the only manifestation or may precede more serious systemic complications of COVID-19. Herein, we describe the first case of ischemic colitis (IC) in a young adult who presented with diarrhea and highlight the laboratory pitfalls for patients with COVID-19 presenting with gastrointestinal (GI) symptoms.
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
Cairns, Junmei , Shepherd, Lois E. , Goss, Paul E. , Barman, Poulami , Goodnature, Barbara, Weinshilboum, Richard M. , Gao, Huanyao , Wang, Liewei , Ingle, James N. , Kalari, Krishna R. , Ellis, Matthew J. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | May 28, 2021 | Volume: 110 | Issue: 4 | Pages: 1038-1049

10.1002/cpt.2311 | PMID 34048027 Get It

Aromatase inhibitors (AIs) are the treatment of choice for hormone receptor–positive early breast cancer in postmenopausal women. None of the third‐generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single‐nucleotide polymorphism (SNP)‐treatment interaction in 4,465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcomes. However, they showed no association with outcome in the combined analysis. We followed up common SNPs near LY75 and GPR160 that could differentiate anastrozole from exemestane efficacy. LY75 and GPR160 participate in epithelial‐to‐mesenchymal transition and growth pathways, in both cases with SNP‐dependent variation in regulation. Collectively, these studies identified SNPs that differentiate the efficacy of anastrozole and exemestane and they suggest additional genetic biomarkers for possible use in selecting an AI for a given patient.
Influence of intra‐aortic balloon pump on mortality as a function of cardiogenic shock severity
Jentzer, Jacob C. , Henry, Timothy D. , Baran, David A. , Barsness, Gregory W. , Holmes, David R. , Henry, Timothy D , Baran, David A , Holmes, David R , Jentzer, Jacob C , Diepen, Sean van

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 28, 2021 | Volume: 99 | Issue: 2 | Pages: 293-304

10.1002/ccd.29800 | PMID 34047486 Get It

AbstractBackgroundRandomized studies of intra‐aortic balloon pump (IABP) in cardiogenic shock (CS) have only included on patients with acute coronary syndromes (ACS) without stratification according to shock severity. We examined the association between IABP and mortality in CS patients across the Society for Cardiovascular Angiography and Intervention (SCAI) shock stages.MethodsWe included cardiac intensive care unit patients admitted from 2007 to 2015 with CS from any etiology. In‐hospital mortality associated with IABP was examined in each SCAI shock stage. Multivariable logistic regression was performed using inverse probability of treatment weighting (IPTW) to determine the association between IABP and in‐hospital mortality.ResultsWe included 934 patients, with a mean age of 68 ± 14 years; 60% had ACS. The distribution of SCAI shock stages was: B, 41%; C, 13%; D, 38%; E, 8%. In‐hospital mortality was lower in the 39% of patients who received IABP (27% vs. 43%, adjusted OR with IABP after IPTW 0.53, 95% CI 0.40–0.72, p < .0001). IABP use was associated with lower crude in‐hospital mortality in each SCAI shock stage (all p < .05, except p = .08 in SCAI shock stage E). We did not observe any significant heterogeneity in the association between IABP use and in‐hospital mortality as a function of SCAI shock stage.ConclusionsPatients with CS who were selected to receive an IABP had lower in‐hospital mortality, without differences in this effect across the SCAI shock stages. Future studies should account for the severity and etiology of shock when evaluating the efficacy of IABP for CS.
Secretome Signature of Cardiopoietic Cells Echoed in Rescued infarcted Heart Proteome
Arrell, D. Kent , Crespo‐Diaz, Ruben , Yamada, Satsuki , Jeon, Ryoung‐Hoon , Garmany, Armin , Park, Sungjo , Adolf, Jeffrey P., Livia, Christopher , Hillestad, Matthew L. , Bartúnek, Jozef , Behfar, Atta , Crespo-Diaz, Ruben J, Jeon, Ryounghoon , Terzic, Andre , Behfar, Atta , Livia, Christopher , Bartunek, Jozef , Terzic, André

Mayo Clinic

Stem Cells Translational Medicine | May 28, 2021 | Volume: 10 | Issue: 9 | Pages: 1320-1328

10.1002/sctm.20-0509 | PMID 34047493 Get It

Abstract Stem cell paracrine activity is implicated in cardiac repair. Linkage between secretome functionality and therapeutic outcome was here interrogated by systems analytics of biobanked human cardiopoietic cells, a regenerative biologic in advanced clinical trials. Protein chip array identified 155 proteins differentially secreted by cardiopoietic cells with clinical benefit, expanded into a 520 node network, collectively revealing inherent vasculogenic properties along with cardiac and smooth muscle differentiation and development. Next generation RNA sequencing, refined by pathway analysis, pinpointed miR-146 dependent regulation upstream of the decoded secretome. Intracellular and extracellular integration unmasked commonality across cardio-vasculogenic processes. Mirroring the secretome pattern, infarcted hearts benefiting from cardiopoietic cell therapy restored the disease proteome engaging cardiovascular system functions. The cardiopoietic cell secretome thus confers a therapeutic molecular imprint on recipient hearts, with response informed by predictive systems profiling.